Mr. Graham Simmonds repors

OSOYOOS RETAINS INTEGRITY MEDIA FOR INVESTOR RELATIONS AND CORPORATE COMMUNICATIONS

Osoyoos Cannabis Inc. has retained Integrity Media Inc. to manage the company's investor relations and corporate communications.

Integrity Media has over two decades working in public markets and is highly experienced with cannabis and psychedelic-based public companies in the United States, Canada, the Caribbean and South America. Integrity Media is led by Kurt Divich, a veteran author and public relations specialist. One of the premier financial copywriters in the industry, Mr. Divich is twice published in fiction and non-fiction and has been highly successful in securing company recognition in elite national financial media.

"Integrity Media is well-known for its exceptional communication and for its devotion to serving shareholders," stated Graham Simmonds, chief executive officer of Osoyoos. "Mr. Divich has been an active consultant to Osoyoos since the very beginning and is ideally skilled to help us transition into our new business model. We are most pleased to have Integrity Media and Kurt on our team."

"It is a distinct pleasure to rejoin Osoyoos and this fantastic team that Graham Simmonds has assembled," stated Mr. Divich. "Osoyoos has entered an exciting and transformative phase as it pursues what I view as one of the greatest new market sectors in the industry armed with tremendous intellectual property via Osoyoos's wholly owned subsidiary AI Pharma and its founder, Dr. Stephen D. Barnhill. I've had the opportunity to listen to Dr. Barnhill share his vision for the company and as it enters into this important, dynamic new phase, Integrity Media will effectively communicate its successes to the investing public, the brokerage community and the media."

About Osoyoos Cannabis Inc.

Osoyoos Cannabis has a joint venture agreement with a private, vertically integrated licensed producer under the Cannabis Act (Canada) to offer contract tolling extraction services to third party businesses. Additionally, the Company recently acquired 1196691 B.C. Ltd. doing business as PCAI Pharma and its wholly owned subsidiary AI Pharmaceuticals Jamaica Ltd., a private corporation incorporated and operating under the laws of Jamaica. The business of AI Pharma involves science, research, treatment, data mining and AI, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi and other psychedelic formulations, and their related medicinal global intellectual property protection.

We seek Safe Harbor.